Corporate & Background
 Custom Manufacturing
 Business & Products
Businesses
Generics
Intermediates
Protected Amino Acids
Chiral Synthesis
Carotenoids (Synthetic) and Nutraceuticals
Products
 Facilities & Strengths
 Ethics & Values
 Regulatory Submissions
 Investors & Financials
 Sustainability
 Careers
 Locations & Contact
 Media Center
 Enquiry
 Home
     Our Nutraceuticals website
      News & Events
 Divi's Labs earns an Income of Rs.366 crores in Q2 of FY12
  Divi's Labs earns a PBT of Rs. 130 crores for Q1 of FY12
  Divi's Labs PAT for Q4 grew by 36% to Rs.175 crores
  Divi's Labs earns an Income of Rs.313 crores for Q3 of FY11
  Divi's Labs earns an Income of Rs.265 crores in Q1
  Divi's Labs earns a PAT of Rs.129 crores for Q4
  Divi's Labs earns an Income of Rs.649 crores for 9M of FY10
  Divi's Labs earns an Income of Rs.445 crores in H1 of FY10
  Divi's Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus
  Divi's Labs PAT for 9 months
grows by 21% to Rs.309 crores
  Divi's Labs PAT for Q2 grows by
49% to Rs.135 crores
  Divi's Labs PAT for Q1 grows by
45% to Rs.94 crores
  Divi's Labs PAT for FY08 grows by 87% to Rs.348 crores
  Divi's Labs PAT for Q3 grows by 216% to Rs.99 crores
  Divi's Labs PAT for Q2 grows by 204% to Rs.91 crores
  Divi's Labs PAT for Q1 grows by 153% to Rs.65 crores
  Divi's Labs PAT for FY07
grows by 167% to Rs.186 crores
  Divi's Labs Q3 total income
 grows by 38% to Rs.152 crores
 Divis successful US-FDA inspection for Unit II
  Divi's Labs Q2 total income
 grows by 97% to Rs.165 crores.
  Divi's Labs Q1 total
 income grows by 142% at
 Rs.165 crores
  Divi's Laboratories earns a
 Net of Rs.19 crores
 on an Income of
 Rs.110 Crores in Q3
 Divis labs SEZs cleared
  Divis Laboratories earns a
 PBT of Rs.43 Crores in
 First-Half of FY06
  Divis Laboratories earns a
 total income of Rs.68
 Crores in Q1 of FY06
  Divis Laboratories earns a
 total income of Rs.365
 Crores in FY05
  Divis Laboratories earns a
 Net of Rs.105 Crores in Q3
  Divis Laboratories earns a
 PBT of Rs.45 Crores in
 First-Half of FY05
  Divis Laboratories earns a
 Net of Rs.14 Crores in Q1
Generics

Divis manufacture API's for the Generics. As a company Divis understand that sustained development is not possible without respecting IPR. Divis takes great care to ensure that its products or processes do not infringe valid patents.

Divis is actively involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.

Intermediates

Divis supplies advanced intermediates for generic APIs that are already out of patent, as also for APIs which are about to enter generic status shortly. Here again, Divis has tie-ups with both original inventors and generic API manufacturers.

Protected Amino Acids

Divis has built up a strong base in the manufacture of BOC, FMOC and CBZ protected amino acids, the protecting reagents themselves, peptide condensing agents, totally synthetic, natural and novel unnatural amino-acids and oligopeptides.

Divis has invested heavily in knowledge, equipment and man-power to expand in this technology area which is sophisticated, challenging and of course rewarding. Currently, Divis is a major manufacturer of protected amino-acids.

Chiral Synthesis

Divis has an established and proven expertise in stereo selective synthesis using chiral ligands, high yield resolutions using chirally active resolving agents, recovery of resolving agents and ligands, recycling of undesirable isomers, resolutions involving enzymes and manufacture of novel ligands like binol, binap and so on.

Carotenoids (Synthetic) and Nutraceuticals

Divis has succeeded in developing multistep total synthesis of important carotenoids like Apocarotenal, Betacarotene, Lycopene, Astaxanthin, Canthaxanthin etc.


Please visit Our Nutraceuticals website

top
Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved     Web design london